Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers

Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era

(2021) Gary H. Lyman et al.   Frontiers in Oncology

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

(2020) Davey Daniel et al.   INTERNATIONAL JOURNAL OF CANCER

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice

(2019) Derek Weycker et al.   BMC CANCER

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer

(2019) Jeffrey Crawford et al.   SUPPORTIVE CARE IN CANCER

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

(2019) Julia Bohlius et al.   Journal of Oncology Practice

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

(2019) J M Weiss et al.   ANNALS OF ONCOLOGY

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis

(2018) Christian L. Barney et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Assessment of costs associated with adverse events in patients with cancer

(2018) William Wong et al.   PLoS One

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status

(2018) Satoshi Igawa et al.   Thoracic Cancer

The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey

(2018) M. Kelsey Kirkwood et al.   Journal of Oncology Practice

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE)

(2017) Shadia I. Jalal et al.   JOURNAL OF CLINICAL ONCOLOGY

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

(2017) Marcello Tiseo et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

(2017) Carsten Bokemeyer et al.   SUPPORTIVE CARE IN CANCER

Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012

(2017) Eric Tai et al.   Journal of Oncology Practice

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)

(2016) M. Aapro et al.   ANNALS OF ONCOLOGY

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

(2016) Yan Sun et al.   BMC CANCER

Platelet Transfusion: A Clinical Practice Guideline From the AABB

(2015) Richard M. Kaufman et al.   ANNALS OF INTERNAL MEDICINE

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

(2015) Pere Gascón et al.   SUPPORTIVE CARE IN CANCER

Transfusions and patient burden in chemotherapy-induced anaemia in France

(2014) Patricia K. Corey-Lisle et al.   Therapeutic Advances in Medical Oncology

Deviations From Guideline-Based Therapy for Febrile Neutropenia in Cancer Patients and Their Effect on Outcomes

(2013) Jason D. Wright et al.   JAMA Internal Medicine

Carboplatin plus etoposide for extensive stage small-cell lung cancer: An experience with AUC 6 doses of carboplatin

(2012) U Yilmaz et al.   INDIAN JOURNAL OF CANCER

Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

(2012) Antonio Rossi et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

(2010) P. Zatloukal et al.   ANNALS OF ONCOLOGY

Risk of mortality in patients with cancer who experience febrile neutropenia

(2010) Gary H. Lyman et al.   CANCER

Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression

(2010) Sumanta Kumar Pal et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

(2008) Andreas Hermes et al.   JOURNAL OF CLINICAL ONCOLOGY